Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by

Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by